Setback for Sunovion's dasotraline in ADHD

The Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said it received a complete response letter for dasotraline (SEP-225289) to treat ADHD.

The company said FDA indicated the need for more efficacy and safety data. Sunovion plans to meet with the agency to discuss next steps...